Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. - Wikidata - wikimedia - TriplyDB

Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

http://www.wikidata.org/entity/Q35109460

about

The Role of Galectin-3 in the Kidneys State of the Art: Newer biomarkers in heart failure The systemic nature of CKD.Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model.Clinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive Treatment Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3.Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure.Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure.Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis.Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.Galectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal Damage Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve.Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction.Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure Galectin 3 complements BNP in risk stratification in acute heart failure.Elevated galectin-3 precedes the development of CKD Incorporating common biomarkers into the clinical management of heart failure Serial galectin-3 and future cardiovascular disease in the general population.Novel biomarkers in chronic heart failure.Clinical use of novel biomarkers in heart failure: towards personalized medicine.The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.Galectin-3: a modifiable risk factor in heart failure.Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.Novel renal biomarkers to assess cardiorenal syndrome Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes.Cardiovascular biomarkers and sex: the case for women.Myocardial interstitial remodelling in non-ischaemic dilated cardiomyopathy: insights from cardiovascular magnetic resonance.Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis.Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives.ST2 and Galectin-3: Ready for Prime Time?Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.Diagnostic and prognostic value of galectin-3, serum creatinine, and cystatin C in chronic kidney diseases.

P2860

Q26752754-89B6474D-0276-4D1F-8E5C-0A59A984EE6C Q27027899-3E5087BA-2941-4291-8E7F-EE5A77C4FD69 Q30234695-D112FB86-3FA4-4542-95C8-85C102650055 Q33606538-6FE98DAB-FDB2-4B84-B1E8-3FC95CE74C8B Q33754895-C8ED525E-075C-4799-B31C-6D2DB74F0098 Q33791650-FDC98D83-FA07-4EBF-AA7D-B8B1BFE05B0D Q33897327-DA959F6D-263E-4C79-9AC7-6397E751C800 Q33912126-0A30557F-12F0-4BD6-B402-D1A7313E5BCC Q34102031-D9112DC7-80FB-4350-A0D5-260639650043 Q35026202-E190F24D-2C3D-4FCC-ADE2-57BDF236AE59 Q35206146-D586E64D-6270-4B01-B968-24E8AE39C55A Q35286926-FEDB4FFE-AEC9-4F51-AAA7-89B86585A142 Q35680958-4690D8EE-5701-4B4D-B029-A3055A4DAF78 Q36003071-1F08284A-48B6-41DF-954D-DAF12206C849 Q36035702-1EBC29A8-1FA8-4D16-8255-25AA5FE37968 Q36187612-F34D0365-D978-4F8E-84D0-08FE27F9DCA2 Q36244494-AA01BA67-2A25-4291-85BE-3A2A69DE1E8C Q36439679-9C6BDBB2-2452-40C6-A7A1-650840323D64 Q36522700-9715FBE3-5C46-4F8B-A872-EF5431C7F682 Q36627699-A498B627-0E82-46C3-9F4A-B0B94E372C1F Q36757833-A41C2F14-07A3-44FA-A7AC-F966FCDFEC7F Q36917873-43583B4F-BA80-473F-899E-F0EC1B51DB54 Q37119904-C44E7E0F-AAFF-45FA-B29A-1DE85A929C1B Q37347009-A589AC8B-5A45-4D30-9B58-39E57DD2C87B Q37580709-5CCA72F2-D565-42C5-A969-289E0C1BD0E3 Q37997237-A500199F-3340-449E-A983-65B67835EF57 Q38109588-4959CA9B-6659-4039-ADD6-B0E0E995BC99 Q38154222-B7552BE7-DF1C-4268-9A5F-268709578241 Q38194209-A5C020F1-065E-46D6-9C53-B87ABEE7CC2F Q38208784-D4CC20BE-5BB0-410F-BBD3-8CB8BC6CDDFC Q38225729-DF1596E5-1635-4CC0-8C93-AD1A420B198B Q38252731-251FD9CE-5156-4B1D-B76D-3895FAD0C37C Q38426618-570B24E2-1D14-4C0A-9B7F-49CC0EA312AC Q38543356-62B43677-3592-41DD-9B73-FA21F8566AE7 Q38596113-B3740BDA-D3BA-4F84-91C0-51A659C867FD Q38727409-18720C7E-33B5-4B3E-A025-3E71C0714C3F Q38756838-A9DEDE1B-926A-4ACC-B85E-C08FD8FCB59F Q38816590-3AE4A3FC-FBD7-4ADA-AE19-FEC51C92CCDA Q38977493-E4EB3C29-DC7D-4008-AC0B-58B75A79D903 Q39303610-4DAEEAD5-0D26-421E-B8B8-CA8326E17F92

P2860

Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

http://www.wikidata.org/entity/Q35109460

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Usefulness of plasma galectin- ...... al insufficiency and survival.

@ast

Usefulness of plasma galectin- ...... al insufficiency and survival.

@en

type

label

Usefulness of plasma galectin- ...... al insufficiency and survival.

@ast

Usefulness of plasma galectin- ...... al insufficiency and survival.

@en

prefLabel

Usefulness of plasma galectin- ...... al insufficiency and survival.

@ast

Usefulness of plasma galectin- ...... al insufficiency and survival.

@en

P1433

Q35109460-3FC1B4C1-B042-4BD6-9553-3A344DD179CF

P1476

Q35109460-4DFED894-20A2-4C7C-B705-044627B44584

P2093

Q35109460-2044DC06-389F-471A-B595-035D619ED14E

Q35109460-6EAEB2E5-61F2-4592-8677-7BB400ED0B49

Q35109460-915BC39A-16F9-4C49-9EDE-4503CB9C02B7

Q35109460-98B18D3B-BC13-4337-B3E7-C45CAAD4DA4A

Q35109460-9B784672-46F8-4DA4-B55A-F10DC8737FC0

Q35109460-ED3B029C-F9A9-48A2-B247-3771FAF54E52

P2860

Q35109460-07F3A111-0C75-46E1-AF6D-53456D1B273E

Q35109460-084E61BD-022A-4700-9B50-D7DEA6E7F58F

Q35109460-235245B7-225C-444C-8708-57B4BEF236B9

Q35109460-31730334-716E-4BA3-9288-40974C6B290A

Q35109460-3832E347-5F16-4564-93D8-69316387B543

Q35109460-41D89029-EB31-49A1-A809-F7F1E62957E4

Q35109460-6DE58625-9286-4219-861D-3F6C68349039

Q35109460-6F65FEB0-F008-439F-8CDA-0A7AE3802AD8

Q35109460-705AD6F9-5D08-4786-B554-2FF7A5558477

Q35109460-7DE85304-6451-487D-94E7-A230D920DF89

P304

Q35109460-C70A1B98-8FB1-44E8-8324-F40C9D812903

P31

Q35109460-D19627AC-FF91-400D-A4E4-AB45ADB910BF

P356

Q35109460-9E79840B-30CF-450F-818E-E8691CC9F024

P407

Q35109460-B3F441DD-A334-4DF7-9E8F-D8E1E5C857C3

P433

Q35109460-6A1ED4A6-CCD9-42D1-8C65-E8F9C894F419

P478

Q35109460-9654B689-DE69-4994-B9CE-554B676B5F85

P50

Q35109460-42FDEFDC-005A-4E63-8312-A992ED1E8F1F

P577

Q35109460-3040C1C1-0E25-4905-86EC-7509AADFFA22

P5875

Q35109460-2F4F9749-8602-4D69-A46D-DFABCC9B3F46

P698

Q35109460-07277245-4898-4CC7-AF8B-1E32088B3B46

P921

Q35109460-1359D5C2-5F73-4E0E-BC6B-CC866563A7BD

Q35109460-54563565-FAEA-4654-B493-EA87A88CF444

P932

Q35109460-064AE792-08F3-4CA4-8F84-3095D0299B94

P356

J.AMJCARD.2011.03.056

P1433

American Journal of Cardiology

P1476

Usefulness of plasma galectin- ...... nal insufficiency and survival

@en

P2093

Allan L Klein

http://www.w3.org/2001/XMLSchema#string

Allen G Borowski

http://www.w3.org/2001/XMLSchema#string

James D Thomas

http://www.w3.org/2001/XMLSchema#string

Kevin Shrestha

http://www.w3.org/2001/XMLSchema#string

W H Wilson Tang

http://www.w3.org/2001/XMLSchema#string

Zhili Shao

http://www.w3.org/2001/XMLSchema#string

P2860

Galectin-3 regulates myofibroblast activation and hepatic fibrosis

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study.

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.

Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.

Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

P304

385-390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AMJCARD.2011.03.056

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Richard W. Troughton

P577

2011-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51154173

http://www.w3.org/2001/XMLSchema#string

P698

21600537

http://www.w3.org/2001/XMLSchema#string

P921

P932

3137764

http://www.w3.org/2001/XMLSchema#string